TransMedics Group (TMDX) Earnings Date, Estimates & Call Transcripts $125.65 -1.90 (-1.49%) Closing price 04:00 PM EasternExtended Trading$126.03 +0.38 (+0.30%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TransMedics Group Earnings Summary TransMedics Group released Q2 2025 earnings on July 30, 2025, reporting an EPS of $0.92, which beat the consensus estimate of $0.48 by $0.44. Quarterly revenue rose 37.7% year-over-year to $157.37 million, above the consensus estimate of $146.64 million. With a trailing EPS of $1.93 and a P/E Ratio of 65.10, TransMedics Group's earnings are expected to grow 43.00% next year, from $1.00 to $1.43 per share. Upcoming Q3 Earnings DateOct. 27After Market ClosesEstimatedConsensus EPS (Jul. 30) $0.48 Actual EPS (Jul. 30) $0.92 Beat By $0.44 Actual Revenue (Jul. 30) $157.37MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckTMDX Upcoming EarningsTransMedics Group's next earnings date is estimated for Monday, October 27, 2025, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get TransMedics Group Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTMDX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TMDX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. TransMedics Group Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251$0.30$0.30$0.30Q2 20251$0.36$0.36$0.36Q3 20251$0.45$0.45$0.45Q4 20251$0.61$0.61$0.61 FY 2025 4 $1.72 $1.72 $1.72 Q1 20261$0.63$0.63$0.63Q2 20261$0.59$0.59$0.59Q3 20261$0.51$0.51$0.51Q4 20261$0.58$0.58$0.58 TransMedics Group Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 10/27/2025(Estimated)--------7/30/2025Q2 2025$0.48$0.92+$0.44$0.92$146.64M$157.37M5/8/2025Q1 2025$0.29$0.70+$0.41$0.70$123.39M$143.54M10/28/2024Q3 2024$0.29$0.12 -$0.17$0.12$115.00M$108.76M7/31/2024Q2 2024$0.21$0.35+$0.14$0.35$98.84M$114.30M4/30/2024Q1 2024-$0.05$0.35+$0.40$0.35$83.78M$96.90M2/26/2024Q4 2023-$0.10$0.12+$0.22$0.12$68.49M$81.20M11/6/2023Q3 2023-$0.18-$0.12+$0.06$0.54$48.05M$66.43M TransMedics Group Earnings - Frequently Asked Questions When is TransMedics Group's earnings date? TransMedics Group has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, October 27th, 2025 based off last year's report dates. Learn more on TMDX's earnings history. What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group issued an update on its FY 2025 earnings guidance on Wednesday, July, 30th. The company issued revenue guidance of $585.0 million-$605.0 million, compared to the consensus revenue estimate of $580.4 million. Did TransMedics Group beat their earnings estimates last quarter? In the previous quarter, TransMedics Group (NASDAQ:TMDX) reported $0.92 earnings per share (EPS) to beat the analysts' consensus estimate of $0.48 by $0.44. Learn more on analysts' earnings estimate vs. TMDX's actual earnings. How can I listen to TransMedics Group's earnings conference call? The conference call for TransMedics Group's latest earnings report can be listened to online. Listen to Conference Call How can I read TransMedics Group's conference call transcript? The conference call transcript for TransMedics Group's latest earnings report can be read online. Read Transcript How much revenue does TransMedics Group generate each year? TransMedics Group (NASDAQ:TMDX) has a recorded annual revenue of $441.54 million. How much profit does TransMedics Group generate each year? TransMedics Group (NASDAQ:TMDX) has a recorded net income of $35.46 million. TMDX has generated $1.93 earnings per share over the last four quarters. What is TransMedics Group's price-to-earnings ratio? TransMedics Group (NASDAQ:TMDX) has a trailing price-to-earnings ratio of 65.08 and a forward price-to-earnings ratio of 125.80. What is TransMedics Group's EPS forecast for next year? TransMedics Group's earnings are expected to grow from $1.00 per share to $1.43 per share in the next year, which is a 43.00% increase. More Earnings Resources from MarketBeat Related Companies SOLV Earnings Results PEN Earnings Results STVN Earnings Results IRTC Earnings Results GKOS Earnings Results BLCO Earnings Results SLNO Earnings Results NVST Earnings Results LIVN Earnings Results INSP Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move Higher This page (NASDAQ:TMDX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access